Please sign in so that we can notify you about a reply
Indications/Uses
Used in angina pectoris and in ischaemia of neurosensorial tissues as in Meniere's disease.
This drug is recommended in: Preventive treatment for episode of angina pectoris.
Adjuvant symptomatic treatment of vertigo and tinnitus (more detected by the ear: whistling, buzzing, which do not correspond to any exterior sounds).
Adjuvant treatment of visual disorders of a circulatory origin.
This drug is recommended in: Preventive treatment for episode of angina pectoris.
Adjuvant symptomatic treatment of vertigo and tinnitus (more detected by the ear: whistling, buzzing, which do not correspond to any exterior sounds).
Adjuvant treatment of visual disorders of a circulatory origin.
Dosage/Direction for Use
Dinemic-SR: One tablet at mealtimes in the morning and evening.
Or as prescribed by the physician.
Or as prescribed by the physician.
Overdosage
Consult a doctor or pharmacist immediately.
Administration
Should be taken with food.
Contraindications
Known hypersensitivity to the active substance or to any of the excipients. This drug is generally not recommended during breastfeeding.
Special Precautions
Use in Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Use In Pregnancy & Lactation
This drug is generally not recommended during breastfeeding.
Use in Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Use in Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Adverse Reactions
Adverse effects most commonly seen with nausea, constipation, dizziness, and headache. Palpitations, tinnitus, vertigo, dry mouth, abdominal pain, vomiting, peripheral oedema, and dyspnoea have been reported. Rarely effects include bradycardia, haematuria, paraesthesia, hypotension, and blurred vision.
Storage
Store at temperatures not exceeding 30°C.
Protect from light, heat and moisture.
Protect from light, heat and moisture.
Action
Pharmacology: Pharmacodynamics: By preserving the energy metabolism in cells exposed to hypoxia or ischaemia, Trimetazidine dihydrochloride prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow whilst maintaining cellular homeostasis.
In man: Controlled studies in angina patients have shown that Trimetazidine dihydrochloride increases coronary flow reserve, thereby delaying the onset of ischaemia associated with exercise, limits rapid swing blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.
Mechanism of Action: Trimetazidine dihydrochloride inhibits mitochondrial long-chain 3-KAT thus favoring glucose oxidation at the expense of fatty acid oxidation, which is impaired. Glucose and fatty acid metabolism in the heart after the formation of acetyl Co-A, both processes follow a common pathway, whereas glucose is able to continue with glycolysis. Oxidation of fatty acids impairs pyruvate oxidation. Trimetazidine dihydrochloride suppresses fatty acid oxidation via inhibition of enzyme 3-KAT, and enhances the process of glucose oxidation. The decrease in fatty acid oxidation and the stimulation of fatty acid oxidation provoked by Trimetazidine dihydrochloride improve the coupling between glycolysis and carbohydrate oxidation. Accordingly, ATP production is achieved with consumption of less oxygen. Moreover, Trimetazidine dihydrochloride stimulates membrane phospholipids turnover during ischemia, thus redirecting fatty acids towards phospholipids. Trimetazidine dihydrochloride regulates ionic and extra cellular exchanges, correcting the abnormal flow of ions across the cell membrane caused by ischemia and preventing cellular edema caused by anoxia. Thus it ensures the functioning of ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
In man: Controlled studies in angina patients have shown that Trimetazidine dihydrochloride increases coronary flow reserve, thereby delaying the onset of ischaemia associated with exercise, limits rapid swing blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.
Mechanism of Action: Trimetazidine dihydrochloride inhibits mitochondrial long-chain 3-KAT thus favoring glucose oxidation at the expense of fatty acid oxidation, which is impaired. Glucose and fatty acid metabolism in the heart after the formation of acetyl Co-A, both processes follow a common pathway, whereas glucose is able to continue with glycolysis. Oxidation of fatty acids impairs pyruvate oxidation. Trimetazidine dihydrochloride suppresses fatty acid oxidation via inhibition of enzyme 3-KAT, and enhances the process of glucose oxidation. The decrease in fatty acid oxidation and the stimulation of fatty acid oxidation provoked by Trimetazidine dihydrochloride improve the coupling between glycolysis and carbohydrate oxidation. Accordingly, ATP production is achieved with consumption of less oxygen. Moreover, Trimetazidine dihydrochloride stimulates membrane phospholipids turnover during ischemia, thus redirecting fatty acids towards phospholipids. Trimetazidine dihydrochloride regulates ionic and extra cellular exchanges, correcting the abnormal flow of ions across the cell membrane caused by ischemia and preventing cellular edema caused by anoxia. Thus it ensures the functioning of ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
MedsGo Class
Anti-Anginal Drugs
Features
Brand
Dinemic
Full Details
Dosage Strength
20 mg
Drug Ingredients
- Trimetazidine
Drug Packaging
Film-Coated Tablet 100's
Generic Name
Trimetazidine Dihydrochloride
Dosage Form
Film-Coated Tablet
Registration Number
DRP-4161
Drug Classification
Prescription Drug (RX)